APPARENT ANTIOXIDANT EFFECT OF 1-DEPRENYL ON HYDROXYL RADICAL FORMATION AND NIGRAL INJURY ELICITED BY MPP-VIVO( IN)

Citation
Rm. Wu et al., APPARENT ANTIOXIDANT EFFECT OF 1-DEPRENYL ON HYDROXYL RADICAL FORMATION AND NIGRAL INJURY ELICITED BY MPP-VIVO( IN), European journal of pharmacology, 243(3), 1993, pp. 241-247
Citations number
48
Categorie Soggetti
Pharmacology & Pharmacy
ISSN journal
00142999
Volume
243
Issue
3
Year of publication
1993
Pages
241 - 247
Database
ISI
SICI code
0014-2999(1993)243:3<241:AAEO1O>2.0.ZU;2-F
Abstract
Using a modified microdialysis procedure, we confirmed that intrastria tal administration of 1-methyl-4-phenylpyridinium ion (MPP+) induced a sustained overflow of dopamine accompanied by increased formation of hydroxyl free radicals (.OH) as reflected by salicylate hydroxylation. Pretreatment with 1-deprenyl (selegiline 60 pmol, intrastriatal perfu sion) significantly decreased the .OH formation elicited by MPP+ (75 n mol). There was a small decrease of dopamine efflux and an insignifica nt change of the ratio of 3,4-dihydroxyphenylacetic acid (DOPAC)/dopam ine following 1-deprenyl pretreatment. These in vivo findings support prior in vitro data that an unique antioxidant property of 1-deprenyl may be independent of its inhibition of type B monoamine oxidase. In a ddition, intranigral co-administration of 1-deprenyl (4.2 nmol) with M PP+ (4.2 nmol) completely protected nigral neurons from probable oxida tive injuries induced by MPP+ (4.2 nmol), as reflected by a near 50% l oss of striatal dopamine ipsilateral to the side of infusion of drug i nto the substantia nigra. This apparent neuroprotective effect of 1-de prenyl on midbrain nigral neurons was also confirmed by histological f indings. The present in vivo data clearly demonstrate that 1-deprenyl can protect nigral neurons against dopamine neurotoxicity produced by MPP+, as suggested by an earlier in vitro study. Thus, 1-deprenyl can preserve the function of MPP+-damaged nigral neurons perhaps by its ap parent antioxidant property in addition to its blockade of the bioacti vation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium metabolites by type B monoamine oxidase.